Brief: Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing
BRIEF-Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing June 4 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
PARABILIS MEDICINES - ESTIMATED IPO PRICE PER SHARE BETWEEN $17 AND $19 - SEC FILING
PARABILIS MEDICINES - ANNOUNCES IPO OF 25 MILLION SHARES - SEC FILING
PARABILIS MEDICINES INC SAYS REGENERON PHARMACEUTICALS AGREED TO BUY ABOUT $75 MILLION OF CO'S COMMON STOCK IN CONCURRENT PRIVATE PLACEMENT
PARABILIS MEDICINES - INTENDS TO USE ABOUT $150 MILLION OF IPO PROCEEDS TO CONTINUE ONGOING CLINICAL DEVELOPMENT OF ZOLUCATETIDE IN DESMOID TUMORS
PARABILIS MEDICINES-TO USE ABOUT $120 MILLION OF PROCEEDS TO CONTINUE ONGOING CLINICAL DEVELOPMENT OF ZOLUCATETIDE ACROSS SEVERAL ADDITIONAL INDICATIONS
PARABILIS MEDICINES-TO USE ABOUT $130 MILLION OF IPO PROCEEDS TO ADVANCE PIPELINE OF ADDITIONAL PROGRAMS
Source text: [ID:n0001193125-26-256398]
Further company coverage: REGN.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)